Oncology and Hematology - Global Oncology Academy

Episodes 1-16 of 107

MinuteCE®
Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
0.25 credits 2 episodes
- Eileen O’Reilly, MD
- Efrat Dotan, MD
0.25 credits 2 episodes
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Project Oncology®
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
- Fernando López-Ríos, MD, PhD
- Christian Rolfo, MD, PhD
- Charlie Gourley, MD, PhD
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
From Guidelines to Practice: First-Line Treatment Choices in mCRC
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
CME/CE
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
0.50 credits
- Elizabeth R. Plimack, MD, MS, FASCO
- Shilpa Gupta, MD
0.50 credits
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Collaborative Insights to Solve the Puzzle of Bladder Cancer
CME/CE
Collaborative Insights to Solve the Puzzle of Bladder Cancer
1.00 credit
- Daniel P. Petrylak, MD
- Elizabeth R. Plimack, MD, MS, FASCO
- Evan Y. Yu, MD
1.00 credit
Patient Perspectives on Bladder Cancer
Patient Perspectives on Bladder Cancer
MinuteCE®
Patient Perspectives on Bladder Cancer
0.50 program credits
- Elizabeth R. Plimack, MD, MS, FASCO
- Lillibeth Velasco, MSN, RN
0.50 program credits
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
MinuteCE®
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
0.50 program credits
- Elizabeth R. Plimack, MD, MS, FASCO
0.50 program credits
Reviewing the Latest Bladder Cancer Practice Guidelines
Reviewing the Latest Bladder Cancer Practice Guidelines
MinuteCE®
Reviewing the Latest Bladder Cancer Practice Guidelines
0.50 program credits
- Elizabeth R. Plimack, MD, MS, FASCO
0.50 program credits
MinuteCE®
Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer
0.50 credits 3 episodes
- Elizabeth R. Plimack, MD, MS, FASCO
- Lillibeth Velasco, MSN, RN
0.50 credits 3 episodes
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CE
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
0.25 credits
0.25 credits
Molecular Profiling for HER2+ Advanced Solid Tumors
Molecular Profiling for HER2+ Advanced Solid Tumors
CME/CE
Molecular Profiling for HER2+ Advanced Solid Tumors
1.00 credit
- Eric Van Cutsem, MD, PhD
- David SP Tan, MBBS, PhD, PRCP
- James Chih-Hsin Yang, MD, PhD
- Kathleen Moore, MD, MS, FASCO
1.00 credit
MinuteCE®
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): From Diagnosis to Treatment
0.25 credits 2 episodes
- Efrat Dotan, MD
- Shubham Pant, MD, MBBS
0.25 credits 2 episodes
Diagnosis and Management of Metastatic PDAC
Diagnosis and Management of Metastatic PDAC
MinuteCE®
Diagnosis and Management of Metastatic PDAC
0.25 program credits
- Efrat Dotan, MD
- Shubham Pant, MD, MBBS
0.25 program credits

Prev
1
2
3
…
6
7
Next

1/6